Aflibercept (Eylea HD)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses aflibercept (Eylea HD) 8 mg/0.07 mL, solution for intravitreal injection. Indication: For the treatment of diabetic macular edema.